Iterum's fu­ture looks un­cer­tain, af­ter lead an­tibi­ot­ic fails con­sec­u­tive piv­otal stud­ies

5 years ago
R&D

Ab­b­Vie grabs SHP2 in­hibitors from Chi­na's Ja­co­bio; Chi-Med set on US fil­ing of su­r­u­fa­tinib

5 years ago
News Briefing

IPOs abound in the time of coro­n­avirus, as For­ma Ther­a­peu­tics pen­cils in $150M Nas­daq de­but

5 years ago
Financing
Startups

Eyes on he­mo­phil­ia prize, Re­gen­eron adds a $100M wa­ger on joint de­vel­op­ment cam­paign with In­tel­lia

5 years ago
Deals
R&D

Covid-19 roundup: Did in­sid­ers cash in on pos­i­tive news re­port about Gilead be­fore pub­li­ca­tion?

5 years ago
Coronavirus

Roche nabs front­line OK for Avastin/Tecen­triq in com­mon liv­er can­cer, best­ing an old Bay­er drug

5 years ago
R&D
FDA+

Ver­sant-backed, Bris­tol My­ers-stamped Re­pare Ther­a­peu­tics guns for $100M IPO

5 years ago
Financing
Startups

My­ovant’s re­l­u­golix wins a piv­otal prostate can­cer show­down with an old stan­dard — com­ing down to the wire on ...

5 years ago
R&D

Bio­Marin holds the line on bleeds with 4-year val­rox up­date on he­mo­phil­ia A — but what's this about an­oth­er de­cline ...

5 years ago
R&D

In a sting­ing set­back, Pfiz­er’s can­cer block­buster Ibrance flops in key ad­ju­vant set­ting

5 years ago
R&D

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise ...

5 years ago
Financing
China

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

5 years ago
R&D
FDA+

As­traZeneca’s $7B ADC suc­ceeds where Roche failed, im­prov­ing sur­vival in gas­tric can­cer

5 years ago
R&D

Once a gem, now just a rock, Take­da punts PhI­II IBD drug as ri­vals mus­cle ahead

5 years ago
R&D

Min­er­va suf­fers an­oth­er CNS de­feat; Eli Lil­ly wins OK for tau-based Alzheimer's di­ag­nos­tic

5 years ago
News Briefing

Sier­ra On­col­o­gy brings on for­mer Aim­mune CEO to the helm; Flag­ship woos ex-No­var­tis ex­ec Fab­rice Chouraqui

5 years ago
Peer Review

Ear­ly sur­vival da­ta boost Zio­phar­m's 'con­trolled IL-12' im­munother­a­py for glioblas­toma

5 years ago
R&D
Cell/Gene Tx

As tislelizum­ab gains trac­tion in Chi­na, BeiGene pulls the cur­tain on NSCLC da­ta sup­port­ing the PD-1 drug

5 years ago
R&D
China

Ku­ra flash­es pos­i­tive HRAS da­ta on once-failed J&J drug

5 years ago
R&D

Af­ter star­ring at ASH last fall, Gilead’s new Forty Sev­en crew col­ors in more promis­ing da­ta for ma­grolimab at AS­CO

5 years ago
R&D

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

5 years ago
R&D

Pfiz­er, Mer­ck KGaA ce­ment Baven­cio blad­der can­cer win with OS da­ta — while carv­ing an­oth­er niche in rare can­cer

5 years ago
R&D
Pharma

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

5 years ago
People
Peer Review

Look­ing to move past an R&D fi­as­co, Ipsen poach­es their new CEO from Sanofi

5 years ago
People
Peer Review
First page Previous page 822823824825826827828 Next page Last page
A service from the Financial Times